Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Closed Solicitation Posted
- Solicitation number
- HT9402-26-Q-9302
- Agency
-
Defense Health Agency
Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- San Antonio, Texas 78230, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Health Agency seeks pharmaceutical pricing quotes for four newly approved drugs under the Department of War Uniform Formulary program, with proposals due May 28, 2026 at 12:00 PM CST and a pre-quotation teleconference on May 13, 2026. Amendment 1 accelerated the original June 29 deadline to May 28.
The four drugs under review are Lifyorli (oncological agents, glucocorticoid receptor antagonist), Quiofic (water-soluble vitamins), Widaplik (antihypertensive agents), and Saphnelo (immunosuppressives), scheduled for Pharmacy and Therapeutics Committee evaluation on August 5–6, 2026. Place of performance is San Antonio, Texas.
Manufacturers may submit two agreement types: Uniform Formulary Blanket Purchase Agreements (UF BPA) for Military Treatment Facilities and TRICARE Mail Order Pharmacy, and Uniform Formulary Additional Discount Program (UF ADP) quotes for TRICARE retail network pharmacies. UF BPA pricing must equal or be lower than Federal Supply Schedule, Big 4, and Joint National Contract pricing and remain valid for 180 days. UF ADP submissions require refund percentages based on Non-Federal Average Manufacturer Price expressed to four decimal places. Quoted discount percentages remain static throughout the agreement term, though calculated refunds may vary annually.
Offerors must be registered in SAM and maintain active Federal Supply Schedule contracts or interim agreements for quoted agents. Submissions must include completed National Drug Code price lists with per-unit and per-NDC pricing for each condition set, a Quote Review Checklist, and fully executed signature pages. The government imposes no purchase obligation. Evaluation weighs relative clinical effectiveness and relative cost effectiveness under 32 CFR 199.21, with the P&T Committee recommending cost-sharing tier classifications (Tier 1 generic, Tier 2 brand, Tier 3 non-formulary, or Tier 4/not covered).
NAICS code is 325412 (Pharmaceutical Preparation Manufacturing); PSC code is 6505 (Drugs and Biologicals).
Notice text
2 versions
Update #2 · Latest ·
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: The following May 2026 newly approved drugs will be reviewed:
a. Lifyorli - Oncological Agents - Glucocorticoid Receptor Antagonist
b. Quiofic - VITAMINS - WATER SOLUBLE
c. Widaplik - ANTIHYPERTENSIVE AGENTS – N/A
d. Saphnelo – IMMUNOSUPPRESSIVES – N/A
The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9302.
Pre-quotation teleconference is on May 13, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
Update #1 ·
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: The following May 2026 newly approved drugs will be reviewed:
a. Lifyorli - Oncological Agents - Glucocorticoid Receptor Antagonist
b. Quiofic - VITAMINS - WATER SOLUBLE
c. Widaplik - ANTIHYPERTENSIVE AGENTS – N/A
d. Saphnelo – IMMUNOSUPPRESSIVES – N/A
The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9302.
Pre-quotation teleconference is on May 13, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
Files
| File | Type | Posted |
|---|---|---|
| A-3 RFQ HT9402-26-Q-9302 . A0001.pdf | ||
| Amendment 1 HT9402-26-Q-9302 . A0001.pdf | ||
| A-3 Price List - Quiofic - Vitamins - Water Soluble.xlsx | XLSX spreadsheet | |
| A-3 Price List - Lifyorli - Oncological Agents - Glucocorticoid Receptor Antagonist.xlsx | XLSX spreadsheet | |
| A-3 DoD Formulary Placement of FDA Newly Approved Drugs.pdf | ||
| A-3 RFQ HT9402-26-Q-9302.pdf | ||
| A-3 Price List - Widaplik - Antihypertensive Agents-NA.xlsx | XLSX spreadsheet | |
| A-3 Price List - Saphnelo - Immunosuppressives - NA.xlsx | XLSX spreadsheet | |
| A-3 Price Appendix FAQ NAD.pdf |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Bayesian Dosing Software | Veterans Integrated Service Network 19 | Total Small Business |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity